SCHEMBL12985477

SCHEMBL12985477

CON(c1ccccc1-c1ccccc1)C(CO)C(=O)O

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 4/20 0.41
TACR1 P25103 2/20 0.40
MEN1 O00255 3/20 0.37
SMN1; SMN2 Q16637 2/20 0.37
KDM4E B2RXH2 4/20 0.37
ALDH1A1 P00352 3/20 0.37
PPARG P37231 2/20 0.37
PPARA Q07869 2/20 0.37
GPR88 Q9GZN0 1/20 0.37
SCN1A P35498 2/20 0.36
SCN2A Q99250 2/20 0.36
SCN3A Q9NY46 2/20 0.36
LMNA P02545 2/20 0.36
USP2 O75604 1/20 0.36
MAPT P10636 1/20 0.36
MAPK1 P28482 1/20 0.36
HTT P42858 1/20 0.36
FGFR1 P11362 1/20 0.36
SRC P12931 1/20 0.36
FGFR2 P21802 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12985138 0.86 TACR1 (0.41) KMT2ATACR1MEN1SMN1; SMN2KDM4E
SCHEMBL12984922 0.80 TACR1 (0.45) KMT2ATACR1MEN1SMN1; SMN2KDM4E
SCHEMBL5281056 0.80 ALDH1A1 (0.38) KMT2AMEN1SMN1; SMN2KDM4EALDH1A1
SCHEMBL5281059 0.80 ALDH1A1 (0.38) KMT2AMEN1SMN1; SMN2KDM4EALDH1A1
SCHEMBL12984499 0.74 KMT2A (0.53) KMT2ATACR1MEN1SMN1; SMN2ALDH1A1
SCHEMBL3963067 0.71 KMT2A (0.59) KMT2APPARGPPARA
SCHEMBL12984894 0.70 MEN1 (0.50) KMT2ATACR1MEN1SMN1; SMN2KDM4E
SCHEMBL12983895 0.69 KMT2A (0.61) KMT2ATACR1MEN1SMN1; SMN2ALDH1A1
SCHEMBL9901515 0.68 ALDH1A1 (0.43) KMT2ATACR1MEN1SMN1; SMN2KDM4E
SCHEMBL2794043 0.68 HPGD (0.39) KMT2AMEN1KDM4EALDH1A1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9414998-B2 Preventing or ameliorating agent for pigmentation POLA CHEMICAL INDUSTRIES INC. (JP) 2016-08-16 US disclosed
US-20140322150-A1 PREVENTING OR AMELIORATING AGENT FOR PIGMENTATION POLA CHEMICAL INDUSTRIES INC. (JP) 2014-10-30 US disclosed
EP-2514402-A1 PROPHYLACTIC OR AMELIORATING AGENT FO PIGMENTATION Pola Chemical Industries Inc. (JP) 2012-10-24 EP disclosed
US-20120258063-A1 PREVENTING OR AMELIORATING AGENT FOR PIGMENTATION POLA CHEMICAL INDUSTRIES INC. (JP) 2012-10-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140322150-A1 PREVENTING OR AMELIORATING AGENT FOR PIGMENTATION TYR, MC1R, MITF KMT2A 1630/4885TACR1 3019/4885MEN1 2910/4885
US-20120258063-A1 PREVENTING OR AMELIORATING AGENT FOR PIGMENTATION TYR, MC1R, MITF KMT2A 1630/4885TACR1 3019/4885MEN1 2910/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.